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Abstract 
This document is a position statement from the Society for Cardiovascular Magnetic Resonance (SCMR) on recom‑
mendations for clinical utilization of cardiovascular magnetic resonance (CMR) in women with cardiovascular disease. 
The document was prepared by the SCMR Consensus Group on CMR Imaging for Female Patients with Cardiovascular 
Disease and endorsed by the SCMR Publications Committee and SCMR Executive Committee. The goals of this docu‑
ment are to (1) guide the informed selection of cardiovascular imaging methods, (2) inform clinical decision‑making, 
(3) educate stakeholders on the advantages of CMR in specific clinical scenarios, and (4) empower patients with clini‑
cal evidence to participate in their clinical care. The statements of clinical utility presented in the current document 
pertain to the following clinical scenarios: acute coronary syndrome, stable ischemic heart disease, peripartum cardio‑
myopathy, cancer therapy‑related cardiac dysfunction, aortic syndrome and congenital heart disease in pregnancy, 
bicuspid aortic valve and aortopathies, systemic rheumatic diseases and collagen vascular disorders, and cardio‑
myopathy‑causing mutations. The authors cite published evidence when available and provide expert consensus 
otherwise. Most of the evidence available pertains to translational studies involving subjects of both sexes. However, 
the authors have prioritized review of data obtained from female patients, and direct comparison of CMR between 
women and men. This position statement does not consider CMR accessibility or availability of local expertise, but 
instead highlights the optimal utilization of CMR in women with known or suspected cardiovascular disease. Finally, 
the ultimate goal of this position statement is to improve the health of female patients with cardiovascular disease by 
providing specific recommendations on the use of CMR.
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Introduction
Cardiovascular magnetic resonance (CMR) imaging is a 
robust, reproducible and safe method for non-invasive 
evaluation of cardiovascular diseases (CVD). Strengths 
of CMR include precise assessment of cardiac anat-
omy and function [1] and multi-parametric tissue 
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characterization [2]. CMR is recommended for diagno-
sis and management of multiple CVDs [3–5]. CMR is 
particularly suitable for the evaluation of women with 
suspected or known CVDs given the lack of ionizing 
radiation exposure, which can be potentially harmful 
to female breast tissue [6, 7] or to the fetus of pregnant 
patients [8]. This is an advantage of CMR compared to 
radiation-based imaging methods including nuclear 
medicine scintigraphy such as single-photon emission 
computerized tomography (SPECT), positron emis-
sion tomography (PET), coronary computed tomog-
raphy angiography (CCTA) and catheter-based X-ray 
angiography.
Recent advances in tissue characterization and 
ischemia assessment make CMR an attractive tool for 
imaging various pathological aspects of cardiovascular 
disease in women [9–13].
Aims and structure of the document
This document provides recommendations for clinical 
utilization of CMR in women with known or suspected 
CVD. We cite published evidence when available and 
provide expert consensus where there is paucity of 
evidence. Most of the evidence available pertains to 
translational studies involving subjects of both sexes. 
However, we have prioritized review of data obtained 
from female patients, and particularly valued the evi-
dence providing direct comparison of CMR between 
women and men.
The women in CMR section of the SCMR has led 
various educational and advocacy initiatives to pro-
mote improved cardiovascular care of females with 
cardiovascular diseases. The group has recently pub-
lished a comprehensive review paper highlighting the 
advantages of CMR for imaging cardiovascular disease 
in women [14]. Building on this initiative, the  SCMR 
Consensus Group on CMR Imaging for Female Patients 
with Cardiovascular Disease  was formed to provide 
guidance for current clinical CMR utilization for this 
purpose. Our committee is primarily composed of 
experts with a wide and representative range of training 
and expertise, a broad geographical representation and 
a balanced spectrum of clinicians and scientists.
The goals of this document, specific for the use of 
CMR in women with known or suspected CVD, are 
to (1) guide the informed selection of cardiovascular 
imaging methods, (2) inform clinical decision-making, 
(3) educate stakeholders on the advantages of CMR in 
specific clinical scenarios, and (4) empower patients 
with clinical evidence to participate in their clinical 
care.
Statement of clinical utility
1. CMR can be used to diagnose ischemic myocardial 
injury in women with suspected acute coronary syn-
drome (ACS), which is particularly important, as 
they are more likely to present with non-obstructive 
coronary arteries compared to men. In addition, 
CMR can reliably establish an alternate diagnosis in 
women with ACS symptoms and suspected diagnosis 
of myocardial infarction with non-obstructive coro-
nary arteries (MINOCA), such as myocarditis and 
Takotsubo cardiomyopathy, which can guide subse-
quent management and may impact their prognosis. 
(Gender neutral evidence).
2. CMR is recommended for diagnosing stable ischemic 
heart disease (IHD) in women. Compared to other 
non-invasive imaging techniques, CMR provides 
high accuracy with no sex differences in performance 
for diagnosis and prognosis in identifying both mac-
rovascular and microvascular coronary artery disease 
(CAD). (Gender neutral evidence)
3. CMR is the recommended method to confirm the 
diagnosis and severity of peripartum cardiomyo-
pathy (PPCM). Detection of presence and extent of 
myocardial damage is valuable for prediction of car-
diac dysfunction and risk stratification in current and 
future pregnancies. (Gender specific evidence)
4. CMR can be used to diagnose cancer therapy-related 
cardiac dysfunction (CTRCD), especially in breast 
cancer patients, and to confirm echocardiography-
diagnosed left ventricular (LV) dysfunction. CMR is 
recommended for myocardial tissue characterization 
in the diagnosis and treatment workup to assess the 
etiology of cardiomyopathy. (Gender neutral evi-
dence)
5. CMR including CMR angiography (CMRA) is the 
preferred imaging modality for serial concomitant 
assessment of aortic valve function and thoracic 
aorta dimensions in patients with bicuspid aortic 
valve (BAV) and aortopathies. (Gender neutral evi-
dence)
6. In women who are planning to become or are cur-
rently pregnant, CMR is recommended in those with 
aortic syndrome, known aortic disease and congeni-
tal heart disease (CHD)  when echocardiography is 
suboptimal. CMR provides assessment of the entire 
aorta, precise quantification of ventricular func-
tion, and localization of left ventricular outflow tract 
(LVOT) obstruction to inform decision making dur-
ing pregnancy. (Gender specific evidence)
7. CMR is indicated for combined functional evalua-
tion and tissue characterization of the myocardium 
and vasculature in patients with systemic rheumatic 
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diseases and collagen vascular disorders, as CMR can 
detect associated myocardial inflammation, provides 
important prognostic information and may lead to 
changes in both cardiac and systemic treatment strat-
egies. (Expert opinion)
8. CMR is a useful and often an essential modality for 
early detection of myocardial disease in female carri-
ers of cardiomyopathy-causing mutations and could 
guide deployment of effective therapies. (Expert 
opinion)
Imaging females with acute coronary syndrome
Clinical scenario
ACS is a leading cause of death worldwide [15]. ACS 
comprise of clinical presentation consistent with acute 
ischemia and includes ST-segment elevation myocardial 
infarction (STEMI), Non- ST-segment elevation myocar-
dial infarction (NSTEMI) and unstable angina.
Sex differences/prevalence There are recognized sex dif-
ferences in the presentation, diagnosis, management and 
treatment of ACS and myocardial infarction (MI) [16–
18]. Women are less likely to present with chest pain and 
often have atypical symptoms, leading to underdiagnosis, 
especially in younger women [19, 20]. Women who do 
present to the emergency department with chest pain are 
investigated less aggressively than men, are less likely to 
receive a correct diagnosis, and are not referred as often 
for guideline-recommended diagnostic and/or therapeu-
tic procedures [21]. Women with ACS are not as likely to 
have significant obstructive CAD on invasive coronary 
angiography and more likely to have ruptured plaque, 
plaque erosion, or thrombus formation [22, 23]. Among 
women with MI and MINOCA, a significant proportion 
show biochemical or imaging evidence of myocardial 
ischemia [22]. Spontaneous coronary artery dissection 
[24], coronary thromboembolism, coronary artery vasos-
pasm, microvascular dysfunction, and Takotsubo stress-
induced cardiomyopathy, are a few of the ACS etiologies 
that need special consideration in women.
Traditional evaluation The standard work-up includes 
assessment of risk factors, history and physical examina-
tion, blood biomarkers for cardiomyocyte damage (e.g., 
troponins) and the electrocardiogram (ECG), Invasive 
coronary angiography, non-invasive cardiac imaging 
modalities such as echocardiography, CCTA and CMR. 
Advanced coronary imaging techniques such as optical 
coherence tomography (OCT), intravascular ultrasound 
(IVUS) are the cornerstone of diagnosis in cases with 
ACS with no or < 50% obstructive CAD. These tests may 
help confirm, refine or reclassify the initial diagnosis, 
which determines treatment pathways and outcomes.
Benefits for use of CMR (gender neutral evidence) CMR 
provides significant incremental value to conventional 
tests in establishing an accurate diagnosis [25–27] 
and prognosis in ACS [28]. CMR plays an important 
role in the contemporary assessment and prognosis of 
MINOCA [26, 29–31]. CMR allows detection of small 
MIs, distinguishing between left anterior descending cor-
onary artery (LAD) territory infarction and Takotsubo 
cardiomyopathy, and differentiating MI from myocardi-
tis. Since women are more likely to present in an atypical 
manner, they should be approached differently than men. 
CMR may help to confirm (or exclude) a diagnosis of 
ACS, so that physicians may provide appropriate timely 
treatment.
Suggested protocol
• Balanced steady-state free precession (bSSFP) cine 
(short and long axis planes) for evaluation of cardiac 
structure, function and potential mechanical compli-
cations from acute MI
• T2-weighted (T2w) imaging for edema imaging 
according to current expert recommendations [30]
• T2* mapping for detection of intramyocardial hem-
orrhage[32] (optional)
• T1-weighted (T1w) late gadolinium enhancement 
(LGE) is the recommended methodology to estimate 
the extent of acute myocardial necrosis and micro-
vascular obstruction (MVO) [32]
• T1w early gadolinium enhancement (EGE) may 
detect LV intracavitary thrombus (can also visualize 
MVO) (optional)
• In stable patients outside of the acute phase, consid-
eration should be given to vasodilatory stress perfu-
sion imaging (adenosine, regadenoson, dipyridamole) 
with gadolinium based contrast agent (GBCA) to 
assess for the functional significance of any bystander 
CAD, and, in particular, microvascular dysfunction.
• Parametric mapping techniques (T1/T2/ extracel-
lular volume fraction (ECV)) are emerging CMR 
technologies that hold promise in providing more 
sensitive detection of acute myocardial injury, includ-
ing assessment of the extracellular volume and myo-
cardial interstitium that may provide further insights 
into differences between women and men who pre-
sent with ACS.
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Stable ischemic heart disease—imaging ischemia
Clinical scenario: IHD is the leading cause of cardio-
vascular death worldwide [33]. Stable IHD includes 
patients who have had ACS or are at risk for ACS, even 
if they have no or limited symptoms. In 2015, there was 
an estimated 110 million patients with IHD worldwide. 
IHD accounts for the majority of CVD in patients over 
40 years, with steady increase in prevalence with age [34]. 
Early detection of these patients is important to decrease 
morbidity and mortality [35]
Sex differences/prevalence: Women have slightly lower 
prevalence of IHD, but higher mortality rate and com-
plications, indicating a potential gap in accurate diagno-
sis and management strategies specific to women [15]. 
In comparison to men, female specific features include 
a higher proportion of symptomatic patients with non-
obstructive CAD and microvasculature dysfunction [36], 
and more frequent presentation with “atypical” angina 
symptoms [37]. As a result, women tend to receive less 
intensive care that lead to higher morbidity, includ-
ing heart failure, and mortality compared to men [38, 
39].Given the higher dissociation between symptoms, 
ischemia burden and obstructive versus non-obstructive 
CAD in women, a more sensitive and “specific” func-
tional evaluation of IHD is warranted for tailored thera-
peutic decisions [40].
Traditional evaluation: Diagnostic testing is recom-
mended in symptomatic stable patients with suspected 
or known IHD and change in clinical status. Functional 
assessment for ischemia with stress testing with or with-
out imaging is the most common method of evaluation. 
The advent of CCTA allows for direct, noninvasive evalu-
ation of the underlying anatomic coronary features in 
IHD and provides an alternative diagnostic method [35].
Benefits for use of CMR (gender neutral evidence): Poorly 
calibrated pre-test probability tables in addition to limi-
tations with achievement of maximum exercise capacity 
are factors that lead to the relatively low diagnostic yield 
of traditional tests like exercise treadmill stress test and 
stress echocardiography for females with IHD [41, 42]. 
CCTA provides high anatomic correlation with inva-
sive X-ray coronary angiography, but given the higher 
dissociation between symptoms, ischemia burden and 
obstructive versus non-obstructive CAD in women, 
functional evaluation of IHD is still warranted for proper 
therapeutic management decisions (Class I, level of evi-
dence B) [43, 44], especially for women. CMR has many 
advantages over other modalities including the lack of 
ionizing radiation, greater sensitivity independent of the 
prevalence of the disease compared to SPECT with no 
sex differences in diagnostic performance [45], ability 
to identify microvascular dysfunction and provide auto-
mated quantitative evaluation of global and regional per-
fusion [46, 47], identification of concurrent myocardial 
scar [9, 48–50], and comprehensive evaluation to exclude 
other cardiac (myocardium, pericardium, valves or great 
vessels) causes of chest pain. While exercise stress CMR 
can be performed with suitable accuracy [51], more com-
mon approaches involve vasodilator stress CMR using 
adenosine, regadenoson or dipyridamole [41]. In the 
latest version of the 2004 American College of Cardiol-
ogy/American heart Association (ACC/AHA) guidelines 
for stable CAD, pharmacological stress CMR is recom-
mended for: diagnosis of IHD in patients with either 
known or intermediate to high pretest probability of IHD 
who are unable to exercise or have uninterpretable ECG 
(Class IIa, level of evidence B); risk assessment in patients 
with known CAD being considered for revascularization 
with unclear physiologic stenosis (Class I, level of evi-
dence B); and follow-up of revascularized stable CAD in 
symptomatic patients (Class I, level of evidence C) [35, 
42]. In the 2019 guidelines from the European Society 
of Cardiology (ESC) of chronic CAD, CMR is recom-
mended for evaluation of patients with suspected coro-
nary microvascular angina (Class IIb, level of evidence B) 
[44].
Suggested protocol
• Rest bSSFP cine (short and long axis planes) for 
evaluation of cardiac structure and function
• Vasodilator stress using conventional doses and 
protocols: induced vasodilation (adenosine, 
regadenoson, dipyridamole) [52]
• Stress first pass perfusion imaging; automated 
quantitative perfusion mapping is recommended if 
available
• T1w LGE (short and long axis planes)
• Native T1-mapping and stress T1-mapping are 
emerging technologies that may play a role in the 
GBCA-free CMR assessment of ischemic heart dis-
ease [53, 54]. ECV may serve as surrogate marker 
for diffuse fibrosis, although resting coronary vas-
odilation associated with ischemia may expand 
the intravascular compartment (thus ECV) in the 
ischemic territory.
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Peripartum cardiomyopathy
Clinical scenario: Peripartum cardiomyopathy (PPCM) 
is a rare form of dilated cardiomyopathy character-
ized by LV systolic dysfunction and LV ejection fraction 
(LVEF) < 45% occurring during late pregnancy or in the 
months following delivery in previously healthy women 
without a history of heart disease. Right ventricular (RV) 
systolic dysfunction may be noted in up to 35% of PPCM 
patients [55] and is linked to worse prognosis than iso-
lated LV involvement. Symptoms are non-specific, such 
as shortness of breath, cough, orthopnea, and hemopty-
sis. Patients may also present with arrhythmias, embolic 
events, and myocardial infarction.
Multiple theories exist to explain PPCM, including 
genetic predisposition, apoptosis, and abnormal immune 
response to fetal microchimerism, abnormal hemo-
dynamic response, prolonged tocolysis, and ethnicity, 
among others [56]. Risk factors predisposing for PPCM 
are advanced age, multiparity and twin pregnancies, Afri-
can American ethnicity, hypertension, and preeclampsia 
[57]
Prevalence: PPCM is a female specific disease with mixed 
and inconsistent reports of incidence. Two of the largest 
population-based studies by Mielniczuk, [58] and Brar 
[59] report mortality of 2.05% in a retrospective study of 
3.6 million patients, with an incidence of approximately 1 
per 3189 live births [55] and mortality of 3.3% in 241,497 
patients with an incidence of 1 in 4025 live births. Inci-
dence greatly varies by ethnicity, with lowest reported 
among Hispanic women and highest among African 
American women.
Traditional evaluation: PPCM is diagnosed during cur-
rent or recent pregnancy and symptoms of heart failure 
in previously healthy woman, family history of heart dis-
ease, abnormal ECG, elevated troponins, and N-terminal 
pro-B-type natriuretic peptide (NT-proNBP). Imaging 
assessment of PPCM is performed using echocardiogra-
phy as the primary modality, CMR for confirmation of 
diagnosis and assessment of severity, and rarely cardiac 
catheterization/endomyocardial biopsies. Therapeu-
tic interventions consider wellbeing of both mother and 
the fetus by informing best type and dosage of medica-
tions. Some patients require continuous monitoring until 
improvement of cardiac function is achieved.
Benefits for use of CMR in this scenario (gender specific 
evidence): Assessment of heart disease without ion-
izing radiation exposure make CMR an optimal imag-
ing modality in pregnancy. Furthermore, CMR helps 
evaluate the other etiology for dilated cardiomyopathy. 
Comprehensive assessment of cardiac function and myo-
cardial damage by CMR assists planning and follow-up 
management of PPCM along with prediction of possible 
PPCM in subsequent pregnancies. The pattern of LGE 
in PPCM is nonspecific and often similar to idiopathic 
nonischemic cardiomyopathy. While some studies failed 
to demonstrate presence of LGE in peripartum cardio-
myopathy [60], others report LGE in up to 40% of cases 
[61].When present, pattern of LGE shows focal and linear 
distribution, involving mid myocardial wall and sub-epi-
cardium [60]61. The presence of LGE is associated with 
increased risk of heart failure decompensation during 
delivery, increased rate of readmissions, and increased 
risk for exacerbation during recurrent pregnancies [62]. 
Inflammatory reaction should be assessed to characterize 
reversible injury.
Suggested protocol
• bSSFP cine (short and long axis planes) for evalua-
tion of cardiac structure and function
• Detection of myocardial inflammation/edema using 
a T2-based method (e.g., T2w imaging or T2-map-
ping)
• Detection of myocardial edema, hyperemia/capillary 
leak, necrosis and fibrosis using a T1-based method 
(e.g., EGE, T1-mapping, ECV and/or T1w LGE) 
according to current expert recommendations [63]
Assessment of cancer therapy‑related cardiac dysfunction 
(CTRCD) in breast cancer patients
Clinical scenario: Chemotherapy, radiation therapy, and 
targeted agents have led to significant improvements 
in the survival rate of women with breast cancer [64]. 
However, these therapies are associated with on-target 
and off-target cardiac side effects, leading to CTRCD 
and substantial cardiac morbidity and mortality. 5-year 
cumulative incidence of heart failure and cardiomyo-
pathy in women receiving combination therapy ranged 
from 7.5% in the young to 36% in the older patients [65]. 
In the latter, CVD is the leading cause of death (15.9%), 
with breast cancer being close but second (15.1%) [66].
Prevalence: Breast cancer is a female predominant dis-
ease, affecting about 1 in 8 women over the course of 
their lifetime, whereas the risk is 1 in 1000 for men [64]. 
There are reported sex disparities in the incidence of 
cancers in other organs, with generally higher incidence 
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in men for most malignancies except for thyroid cancer 
which is more prevalent in women [67].
Traditional evaluation: Guideline driven evaluation 
and monitoring of cardiac function of women undergo-
ing oncologic treatment is traditionally performed with 
transthoracic echocardiography (TTE), and preferably 
with three-dimensional (3D) LVEF and LV strain assess-
ment [68–70]. A 10% change in LVEF may dictate the 
therapeutic regimen [70]. However, up to 25% of patients 
with cardiac dysfunction (LVEF < 50%) are missed with 
two-dimensional (2D) TTE [71]. In addition, 2D echo-
cardiography has higher temporal variability (9.8%) than 
3D echocardiography (5.6%) [72].which should be kept in 
mind when evaluating these patients. LVEF can equally 
be assessed accurately with multi-acquisition gated angi-
ography (MUGA) as well as CMR and 3D echocardiog-
raphy [73]. However, MUGA is not preferred owing to 
the ionizing radiation, which is a significant concern in 
women with breast cancer.
Benefits for use of CMR in this scenario (gender neutral 
evidence): CMR can be used as a first line method or 
when echocardiographic image quality is inadequate for 
volumetric and functional assessment of patients at risk 
for CTRCD, according to societal guidelines [74]. Fur-
thermore, when echocardiography is abnormal (e.g., 
change in LVEF), CMR should be performed to con-
firm the altered LVEF prior to making decisions about 
management. Additionally, CMR should be used for 
tissue characterization and evaluation of ischemic and 
non-ischemic scar or fibrosis and inflammation, such as 
may occur in trastuzumab related cardiomyopathy and 
immune-checkpoint inhibitor myocarditis [75]. CMR 
strain imaging has been shown to decrease post anthra-
cycline use [76] although currently no inter-vendor 
normal reference values has been established to guide 
management. T2w imaging with increased signal inten-
sity have been observed in patients post anthracycline 
and trastuzumab [77, 78]. T1 mapping and ECV has been 
observed to increase after anthracycline exposure [79, 
80], although their clinical significance and influence on 
patient management is yet to be determined. Stress per-
fusion CMR to detect or exclude functionally significant 
CAD in women [45] should be added if there is suspicion 
for or if necessary to exclude CAD prior to proceeding 
with surgery or other therapy where indicated.
Suggested protocol
• Non-contrast study for those receiving serial imaging 
for screening of LV dysfunction in lieu of echocardi-
ography
• bSSFP cine (short and long axis planes) for evalua-
tion of cardiac structure and function
• Consider further tissue characterization for myo-
cardial inflammation and other changes using T2w 
imaging and/or parametric T1/T2 mapping and ECV 
(optional)
• T1w LGE in suspected cardiomyopathy
• Stress first-pass perfusion to assess for functionally 
significant CAD prior to surgery or other therapy if 
indicated
Baseline and follow aortic assessment in bicuspid aortic 
valve
Clinical scenario: Bicuspid aortic valve (BAV) disease 
affects 0.5–1% of the population with a male predomi-
nance of 3:1 [81]. BAV is associated with aortic valve 
dysfunction (i.e. stenosis or regurgitation) and thoracic 
aortic disease, including ascending aortic aneurysm 
and aortic dissection [82]. Thoracic aortic dilatation 
is thought to be independent of degree of valve steno-
sis and has been associated with reduced fibrillin in the 
aortic wall and/or genetic defects (e.g. NOTCH 1 gene) 
[83]. Many women with BAV are asymptomatic, how-
ever, when they do develop symptoms, they are related 
to aortic valve dysfunction, aortopathy (i.e., aneurysm, 
dissection) and acquired conditions such as endocarditis. 
Guidelines recommend screening first-degree relatives 
of patients with BAV for BAV and associated aortopathy 
[84]. Patients with BAV should be monitored for pro-
gressive aortic valve dysfunction and aortic disease. Sur-
veillance is commonly performed with serial imaging at 
intervals between 6  months and 5  years depending on 
patient age and degree of underlying pathology [84, 85].
Sex differences/prevalence: Morphology type of BAV is 
similar between men and women. At initial presentation, 
men more frequently demonstrate moderate to severe 
aortic regurgitation, whereas women more commonly 
show moderate to severe aortic stenosis. Women are less 
likely to develop endocarditis or concomitant aortopathy 
compared to men [86, 87]. Despite less baseline mor-
bidity compared to men, women exhibit a significantly 
higher mortality in tertiary and surgical referral cohorts, 
which can be independently predicted by presence of 
significant aortic regurgitation and/or New York Heart 
Association (NYHA) Class 3 or 4 heart failure symptoms 
[87]. The reasons for the excess mortality in women may 
relate to use of absolute as opposed to indexed cutoff val-
ues for referral to aortic valve or aorta surgery in which 
men will reach earlier than women as they have larger 
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body surface area (BSA) values. Pregnancy in women 
with BAV is associated with an increased risk for com-
plications [88] and women who may become or are preg-
nant should receive appropriate counseling (see section 
on “Pregnancy risk stratification for congenital heart dis-
ease and aortopathy”).
Traditional evaluation: Echocardiography is the pre-
ferred method for diagnosing BAV disease with reported 
high sensitivity, although diagnosis can be limited in 
patients with heavily calcified valves [89]. Visualization 
of the thoracic aorta is limited to the aortic root and 
ascending aorta with TTE. If the ascending aorta is not 
well visualized on echocardiography, then computed 
tomography angiography (CTA) or magnetic resonance 
angiography (MRA) is recommended. ECG gated CTA 
provides excellent visualization of the entire thoracic 
aorta with high resolution but has the disadvantage of 
radiation exposure and requirement for iodinated con-
trast. Assessment of the aortic valve with CTA requires 
a retrospectively gated acquisition, generally associated 
with higher radiation exposure, which is particularly rel-
evant in young women exposure of the breast tissue (see 
section on “Radiation”). For patients with BAV, annual 
CTA or MRA is recommended if aortic root or ascending 
aorta is 3.5–4.4 cm, and with echocardiography to follow 
valve disease, if needed; for dimensions of 4.5–5 cm, bi-
annual CTA or MRA is recommended.
Benefits for use of CMR (gender neutral evidence): CMR 
and MRA have the advantage of providing a comprehen-
sive assessment of the aortic valve and the entire thoracic 
aorta in a single examination without radiation expo-
sure. Direct planimetric measurement of the aortic valve 
area can be achieved using bi-orthogonal short axis cine 
images of the aortic valve. Non-contrast MRA techniques 
are available which mitigates any risk related to gadolin-
ium deposition, which may be of particular concern with 
serial surveillance.
Suggested protocol
• bSSFP cine (short and long axis planes) for evalua-
tion of cardiac structure and function. Multiplanar 
bSSFP cine with specific views of the aortic valve and 
aorta
• Axial T1w fast spin echo through aorta (optional, for 
intramural hematoma, dissection)
• Axial T2w gradient echo through aorta (optional, for 
aortitis)
• 2D phase contrast velocity encoding at aortic root for 
aortic flow (or four-dimensional flow if available)
• 3D contrast enhanced or non-contrast MRA of the 
thoracic aorta
• Orthogonal dimensions of the aorta should be 
obtained from 7 anatomic landmarks in the thoracic 
aorta, according to the American Heart Association 
guidelines [90]
Pregnancy risk stratification for congenital heart disease 
and aortopathy
Clinical scenario: CVD is a leading cause of morbid-
ity and mortality in pregnant women [91]. Women with 
CVD particularly women with congenital heart dis-
ease (CHD) who are contemplating pregnancy should 
undergo a complete work-up including appropriate car-
diac imaging for risk stratification prior to conception. 
For women with connective tissue disorders, pregnancy 
may be associated with progressive dilatation of the aorta 
secondary to estrogen effects, increased protease activity 
in the extracellular matrix and defective collagen synthe-
sis [92]. Aortic dissection remains the greatest concern 
as it is associated with high maternal mortality, with 
increased risk in both the antepartum and postpartum 
periods [93]. Syndromes with high risk for aortic dissec-
tion include Marfan [94], Loeys-Dietz and Ehler Danlos 
type IV (vascular type). Other syndromes in which there 
is an increased risk of dissection include BAV and Turner 
syndrome. In women with Marfan syndrome, the aortic 
root size may not return to the pre-pregnancy dimen-
sions and there appears to be an increased risk of future 
aortic events or need for aortic root replacement after 
pregnancy [95].
Prevalence: Approximately 1–4% of pregnant women 
have underlying CVD [96]. The rising incidence of CVD 
in pregnancy is related to a number of factors includ-
ing advancing maternal age with associated increased 
prevalence of CVD risk factors and increasing number 
of women with CHD who reach childbearing age. CHD 
comprises at least 50% of CVD in pregnancy [97].
Traditional evaluation: Imaging is an important compo-
nent of the evaluation before and during pregnancy [98]. 
Several risk stratification models have been developed 
summarizing maternal and fetal outcomes in women 
with CVD [99]100. Specific imaging factors included in 
these models that confer a higher risk of adverse events 
in pregnancy include depressed systemic ventricular 
function, obstructive morphology, pulmonary hyperten-
sion and aortopathy [100, 101].While TTE remains the 
first line imaging modality for CVD in pregnancy, many 
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women with CHD undergo CMR for cardiovascular sur-
veillance and risk stratification prior to pregnancy [98]
Benefits for use of CMR (gender specific evidence): In spe-
cific CHD populations, CMR studies have identified risk 
factors for adverse maternal outcomes in pregnancy. As 
an example, descending thoracic aortic diameter < 1.2 cm 
was correlated with higher maternal cardiovascular 
events in patients with aortic coarctation [99] and mater-
nal cardiac events (cardiac arrest and arrhythmias) were 
associated with a systemic RV ejection fraction (RVEF) 
of < 35% [99] in women with atrial switch procedure for 
transposition of great arteries. CMR is particularly use-
ful in women with aortic disease during pregnancy. The 
2018 ESC Guidelines for Management of Cardiovascu-
lar Disease during Pregnancy states that imaging of the 
entire aorta with CMR or CTA is recommended before 
pregnancy in patients with a genetically proven aortic 
syndrome or known aortic disease (Class I, level of evi-
dence C). During pregnancy, CMR (without GBCA) is 
recommended for imaging the distal ascending aorta, 
aortic arch, or descending aorta (Class I, level of evidence 
C) or when other non-invasive diagnostic testing is not 
sufficient for definitive diagnosis (Class IIa, level of evi-
dence C) [96, 102]. The use of GBCA should be avoided, 
if possible, especially in the first trimester. A recent mul-
ticenter study including 83 pregnant women with vas-
cular disease, CHD and cardiomyopathies has shown 
that management plans were changed in 35% of patients 
based on the CMR findings [103].
Suggested protocol
• Patients should be imaged supine position.
• For patients > 20 weeks’ gestation, the use of a wedge 
or pillow under right buttock to tilt pelvis off the 
vena cava is recommended.
• If GBCA is necessary to answer the clinical question, 
a low-risk agent with the minimum possible amount 
should be used.
• 3D MRA of the chest can be performed with GBCA 
or using inherent increased signal of the blood pool 
with navigator-compensated and ECG-gated 3D 
bSSFP sequence.
• bSSFP cine sequences in the axial, oblique sagittal, 
and aortic orifice view planes are useful for precise 
measurement of maximum aortic size, particularly at 
the sinus of Valsalva where the most motion artifact 
is seen with standard 3D MRA.
• bSSFP cine (short and long axis planes) for evalua-
tion of cardiac structure and function
• If there are concerns about the patient, communica-
tion with the obstetrical team is critical.
• Parametric T1 and T2 mapping holds promise to 
provide GBCA-free myocardial tissue characteriza-
tion in the future, and may be particularly suitable for 
this patient group.
Cardiovascular assessment in patients with systemic 
diseases
Clinical scenario: Rheumatoid arthritis, spondyloar-
thropathies, systemic lupus erythematosus, systemic vas-
culitis, inflammatory myopathies, systemic sclerosis and 
mixed connective tissue disease are autoimmune rheu-
matic diseases (ARD) with high incidence of CVD [104]. 
Although targeted treatment has significantly decreased 
the disease-related mortality, life expectancy in ARD 
patients still remains low compared to the general popu-
lation [105], mainly due to increased CVD [106–110]. 
There are several pathophysiologic processes that con-
tribute to the development of CVD in patients with ARD, 
including myocardial/vascular inflammation [111–113], 
macro- and micro- vasculopathy [114, 115], and small 
epicardial, intramyocardial and/or subendocardial fibro-
sis due to inflammation and/or myocardial infarction 
[114, 116, 117]. These processes are not well evaluated 
by traditional imaging techniques, and an ideal diagnos-
tic evaluation would include assessment of the acuity 
of heart involvement [113, 118, 119] and angiography 
of the great vessels with assessment of the arterial wall 
inflammatory process [116]. Iron overload states rep-
resent another relevant systemic disease that can affect 
the heart. Iron overload cardiomyopathy (IOC) results 
from genetic iron metabolism disorders (primary hemo-
chromatosis) or multiple transfusions (thalassemia or 
myelodysplasia).
Sex differences/prevalence: ARD affect 8% of the popu-
lation and approximately 78% of patients are women 
[120]. Sex differences are the result of various factors, 
including sex hormones, microchimerism, genes on X 
or Y chromosomes, X chromosome inactivation and 
differing responses to environmental factors. Estrogens 
may directly increase ARD in women by elevating auto-
antibodies and amplifying autoreactive T- and B-cell 
responses [121]. Myocardial iron overload (MIO) is seen 
approximately 30% of patients with thalassemia [122, 
123] Although men and women have a similar risk of 
iron accumulation, women have significant lower risk for 
cardiac dysfunction, heart failure and arrhythmias com-
pared to men[122].
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Traditional evaluation: The standard evaluation of ARD 
patients with suspected CVD often includes clinical his-
tory and examination, ECG, TTE, 24-h cardiac ECG 
monitoring, nuclear imaging and invasive x-ray coronary 
angiography, if necessary. However, the silent presenta-
tion of cardiac involvement in ARD patients is difficult 
to detect and may hamper comprehensive clinical evalu-
ation and treatment. The limited tissue characterization 
of TTE leads to under-diagnosis of early myocardial 
involvement, which may lead to fatal arrhythmias despite 
preserved LV and RV function [124]. Nuclear imaging 
techniques may miss small perfusion/fibrosis defects due 
to inherently low spatial resolution. Annual ECG, 24  h 
ECG monitoring, and TTE are generally used in the eval-
uation and follow-up of patients with suspected MIO.
Benefits for use of CMR (expert opinion): CMR provides 
significant advantages over other imaging techniques in 
the assessment of CVD in ARD patients, owing to CMR’s 
high spatial resolution and ability to detect small myo-
cardial and vascular changes. In patients with suspected 
IOC, the highly reproducible and sensitive CMR T2* 
technique has revolutionized management, providing 
noninvasive, quantitative and validated MIO assessment 
[118, 125, 126]. Initial cardiac T2* assessment should be 
performed as early as possible in the course of the dis-
ease. Annual CMR assessment is recommended, but 
can be repeated every 2  years in patients without MIO 
or in women given the lower CVD risk [126, 127]. Pre-
cise assessment of degree of iron deposition that can 
inform chelation therapy in patients with MIO. Compre-
hensive CMR examination allows for evaluation of the 
various pathophysiologic processes that may be present 
in patients with ARD and MIO. CMR adds to the diag-
nosis and management of CVD in ARD and MIO based 
on the assessment of myocardial ischemia and replace-
ment or diffuse fibrosis [115, 117, 119, 128–130], disease 
acuity and extent [112, 114, 117, 128–132] due to either 
macro- or micro-vascular coronary artery disease. It also 
helps with etiology of silent/overt heart failure or rhythm 
disturbances [112, 133].High accuracy of stress CMR is 
valuable for early assessment of CAD [117].
Suggested protocol
• bSSFP cine (short and long axis planes) for evalua-
tion of cardiac structure and function
• Detection of myocardial edema/inflammation using a 
T2-based method (e.g. T2w imaging or T2-mapping) 
according to current expert recommendations [63]
• Detection of myocardial edema, hyperemia/capillary 
leak, necrosis and fibrosis using a T1-based method 
(e.g., early gadolinium enhancement, T1-mapping, 
ECV and/or T1w LGE) according to current expert 
recommendations [63]
• Stress-rest first pass perfusion for evaluation of myo-
cardial ischemia (optional, if there is relevant clinical 
question)
• T2* mid short axis (optional basal, mid and apical 
short axis) when MIO is suspected
CMR in female carriers of heritable cardiomyopathies
Clinical scenario: A genetic carrier is an individual with 
a mutation, typically recessive, in an allele or one copy 
of a gene [134]. Female carriers differ from males in 
recessive mutations on the X chromosome. Historically, 
female cardiogenetic carriers were thought to be immune 
to X-linked disease manifestations, having 2 X chro-
mosomes. However, carriers may incur mild to severe 
phenotypic changes with mutations for dilated (such as 
Duchenne and Becher muscular dystrophy [135] and 
Danon’s disease [136] and hypertrophic (e.g. Anderson-
Fabry disease) cardiomyopathies [137]. Disease pen-
etrance often occurs later in life for carrier women vs. 
affected men. Cardioprotective therapies have been 
proven efficient when structural or functional abnormali-
ties are present, even prior to symptom onset—a state 
known as ‘stage B cardiomyopathy’ [138]. Thus, clinical 
recognition of carrier status is important to facilitate 
cardiac risk assessment and management. With increas-
ing acknowledgement of the risk of cardiomyopathy in 
female carriers, early detection with CMR provides guid-
ance for deployment of effective therapies in female car-
riers of cardiomyopathy-causing mutations.
Prevalence: The prevalence of mutations that place 
women at risk of cardiomyopathy is not known but likely 
under-recognized, and genetic testing remains limited in 
its use to evaluate ‘idiopathic’ cardiomyopathy. Genetic 
testing of mothers or female siblings of males with 
X-linked cardiomyopathies are recommended and should 
be more widely practiced [68, 135–140].
Traditional evaluation: Female carriers may be screened 
by compiling a pedigree, clinical history, physical exami-
nation, ECG, and imaging, typically TTE. In the absence 
of cardiac symptoms, carriers may undergo no further 
testing. However, CMR is variably used to screen asymp-
tomatic carriers or evaluate those with symptoms.
Benefits for use of CMR in this scenario (expert opinion): 
CMR uniquely identifies myocardial changes resulting 
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in female carriers well before typical measures of cardiac 
function are abnormal. Tissue characterization coupled 
with biventricular function quantification constitutes the 
major benefit of using CMR. Female mutation carriers of 
Duchenne, Danon and Anderson-Fabry’s diseases have 
varying degrees of myocardial damage by CMR even with 
normal LV size and function, before apparent heart fail-
ure or sudden death occur [136, 137, 141]
Suggested protocol
• bSSFP cine imaging for cardiac functional and volu-
metric assessment according to societal guidelines 
[74]
• T1w LGE, typically showing epicardial or midwall 
fibrosis in X-linked cardiomyopathies, and to exclude 
ischemic damage [42, 140]
• Further tissue characterization using Tw imaging 
and/or parametric T1/T2 mapping, particularly T1 
mapping in Anderson-Fabry disease carriers [142] or 
in unclear LV hypertrophy
Safety considerations related to magnetic field 
and contrast media
i. Magnetic field considerations
CVD remains a major cause of morbidity and mortal-
ity in pregnant and post-partum women [143]. Although 
pregnancy is not a contraindication to magnetic reso-
nance imaging (MRI), heating by radiofrequency pulses 
and effects of acoustic noise on the fetus have been raised 
as potential concerns. However, a retrospective study 
in 754 neonates who had 1.5  T MRI in utero showed 
no effect on hearing function or birth weight compared 
to control neonates [144]. Further in a large retrospec-
tive study in Canada that analyzed 1737 pregnancies 
with MRI, an exposure to MRI was not associated with 
a higher risk of stillbirth or neonatal death, congenital 
abnormalities, neoplasm or hearing loss when compared 
to 1.4 million pregnancies without MRI [145]. Therefore, 
recent results suggested that non-contrast enhanced MRI 
appears to be safe in pregnant women. Of note, due to 
increased heating effect and lack of safety data at 3 T, it is 
recommended to avoid MRI at > 1.5 T during pregnancy.
 ii. Contrast media considerations
GBCA can cross the placenta and is excreted by the 
fetal kidneys into the amniotic fluid, and then returns 
to the fetal circulation by swallowing. Although the 
amounts of gadolinium chelate in the fetal tissues and 
amniotic fluid were much smaller than the maternal 
injected dose, prolonged recirculation of the contrast 
medium in fetal tissue can cause adverse effects [146]. 
In a retrospective study of Canadian provincial pregnan-
cies from 2003 to 2015, GBCA MRI during pregnancy 
was associated with higher risk of stillbirth or neonatal 
death and a broad set of rheumatological, inflammatory, 
or infiltrative skin conditions, compared to the control 
group who did not undergo MRI during pregnancy [145]. 
Accordingly, GBCA should only be used if contrast-
enhanced CMR is considered critical and the potential 
benefits justify the potential risk to the fetus [147]. When 
there is a very strong indication for contrast-enhanced 
CMR, the smallest possible dose of a macrocyclic GBCA 
may be given to the pregnant women [146].
Previously, some centers have recommended avoidance 
of breast feeding for 24 h after administrating GBCA in 
lactating women. However, less than 0.04% of the total 
maternal dose of intravenous GBCA passes into the 
breast milk over 24 h, with only a small fraction of this 
amount absorbed from the gastrointestinal tract [148].
Therefore, according to the current guidelines  [146, 
147], breast feeding may be continued when macrocyclic 
GBCA are given to the mother.
Conclusion
This document summarizes the recommendations of the 
SCMR Consensus Group on CMR Imaging for Female 
Patients with Cardiovascular Disease. After thorough 
review of current evidence and major society guidelines, 
and input from experts in the field, the group has pro-
posed eight clinical applications where CMR is particu-
larly useful in the assessment of female cardiovascular 
diseases.
The position statement does not consider CMR acces-
sibility or availability of local expertise, but instead high-
lights the optimal utilization of CMR in women with 
cardiovascular disease. Finally, the ultimate goal of this 
position statement is to improve the health of female 
patients with cardiovascular disease by providing specific 
recommendations on use of CMR.
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